^sup 18^F-FDG PET as a Surrogate Biomarker in Non-Small Cell Lung Cancer Treated with Erlotinib: Newly Identified Lesions Are More Informative Than Standardized Uptake Value by ProQuest

VIEWS: 11 PAGES: 9

More Info
									18F-FDG PET as a Surrogate Biomarker in Non–Small Cell
Lung Cancer Treated with Erlotinib: Newly Identified Lesions
Are More Informative Than Standardized Uptake Value
Thomas Bengtsson1, Rodney J. Hicks2, Amy Peterson3, and Ruediger E. Port4
1Biostatistics, Genentech Inc., South San Francisco, California; 2Centre for Cancer Imaging, Peter MacCallum Cancer Centre,

Melbourne, Victoria, Australia; 3Early Clinical Development, Genentech Inc., South San Francisco, California; a
								
To top